NK:IO develops novel NK cell and small molecule therapies to overcome limitations in current cancer immunotherapy approaches. The company utilizes proprietary platform technologies to enhance NK cell expansion and tumor-killing capacity for treating solid and hematological tumors. Their focus is on creating highly functional NK cell therapeutics that avoid the exhaustion phenotype seen in competing technologies.
Funding
Funding not disclosed
Founders
Product
Problem
Current natural killer (NK) cell therapies face limitations in achieving sufficient cell numbers for effective treatment and often exhibit rapid exhaustion, reducing their cytotoxicity against tumors. This restricts the potential of NK cell-based immunotherapies for both hematological and solid tumors.
Solution
NK:IO is developing NK cell and small molecule therapeutics derived from umbilical cord blood stem cells to enhance NK cell expansion and cytotoxicity. The company's platform technologies address the challenges of NK cell therapy by leveraging novel mechanisms in NK cell development. NK:IO's approach involves a synergistic combination of small molecule antagonists and recombinant protein ligands to drive enhanced NK cell expansion. The resulting NK cells are highly functional, engineered to exhibit enhanced cytotoxic and tumor cell-sensing properties, and do not display the exhaustion phenotype commonly observed in other NK cell technologies. Furthermore, NK:IO is developing small molecules to mobilize and enhance NK cell production in vivo, offering a novel approach to bolster the immune system's anti-tumor responses and tackle long-term pathogen infections.
Target Audience
The primary target audience includes researchers and clinicians focused on cancer immunotherapy, particularly those seeking to improve the efficacy and scalability of NK cell-based therapies for hematological and solid tumors.
Features
- wNK:IO Cells: First-generation human NK cells derived from umbilical cord blood stem cells, expanded using a synergistic combination of a small molecule antagonist and recombinant protein ligand.
- eNK:IO Cells: Next-generation engineered NK cells produced by deleting relevant inhibitory receptors, resulting in enhanced cytotoxic and tumor cell-sensing properties.
- dNK:IO REV-ERB Antagonists: Small molecules designed to mobilize and enhance NK cell production in vivo.
- Platform technologies target both haematological and solid tumours such as ovarian cancer.